H. Lundbeck A/S (HLBBF)
Market Cap | 5.95B |
Revenue (ttm) | 3.21B |
Net Income (ttm) | 401.88M |
Shares Out | n/a |
EPS (ttm) | 0.41 |
PE Ratio | 14.81 |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,000 |
Open | 6.10 |
Previous Close | n/a |
Day's Range | 6.10 - 6.10 |
52-Week Range | 4.63 - 7.13 |
Beta | 0.21 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Nov 13, 2024 |
About H. Lundbeck
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company’s principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat M... [Read more]
Full Company ProfileFinancial Performance
In 2023, H. Lundbeck's revenue was 19.91 billion, an increase of 9.13% compared to the previous year's 18.25 billion. Earnings were 2.29 billion, an increase of 19.52%.
Financial numbers in DKK Financial StatementsNews
Longboard Pharmaceuticals HSR waiting period expires for Lundbeck deal
Longboard Pharma's Lucrative Exit To Lundbeck Another Coup For Management
NVIDIA, Trump Media & Technology, Bausch + Lomb, Sirius XM And Other Big Stocks Moving Higher On Monday
U.S. stocks were higher, with the Dow Jones index gaining around 150 points on Monday. Shares of NVIDIA Corporation (NASDAQ: NVDA) rose during Monday’s trading session. A government-backed think tank...
Top 1% Biotech Longboard Scores A $2.6 Billion Deal And Skyrockets To A Record
Lundbeck announced Monday it would buy Longboard Pharmaceuticals in a $2.6 billion deal that sent Longboard stock to a record high.
Longboard Pharmaceuticals’ stock soars amid Lundbeck’s $2.6 billion deal to acquire the company
H. Lundbeck plans to acquire Longboard Pharmaceuticals in a $2.6 billion deal, the companies announced Monday.
Lundbeck to Acquire Longboard Pharmaceuticals (LBPH) for $2.6 Billion
Lundbeck to Acquire Longboard Pharmaceuticals (LBPH) for $2.6 Billion
Why Is Epilepsy Focused Longboard Pharmaceuticals Stock Trading Higher On Monday?
H. Lundbeck acquires Longboard Pharmaceuticals for $2.6 billion. ... Full story available on Benzinga.com
Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 47%; Here Are 20 Stocks Moving Premarket
Shares of Longboard Pharmaceuticals, Inc. (NASDAQ: LBPH) rose sharply in today's pre-market trading . Lundbeck agreed to acquire Longboard Pharmaceuticals in a transaction valued at approximately $2....
Lundbeck to Buy Longboard Pharmaceuticals in $2.6 Billion Deal
Danish pharmaceutical company H. Lundbeck A/S has agreed to acquire Longboard Pharmaceuticals Inc in a deal with an equity value of $2.6 billion.